HUE042802T2 - Kombinációs terápia tumorellenes antibiotikummal - Google Patents

Kombinációs terápia tumorellenes antibiotikummal

Info

Publication number
HUE042802T2
HUE042802T2 HUE14175259A HUE14175259A HUE042802T2 HU E042802 T2 HUE042802 T2 HU E042802T2 HU E14175259 A HUE14175259 A HU E14175259A HU E14175259 A HUE14175259 A HU E14175259A HU E042802 T2 HUE042802 T2 HU E042802T2
Authority
HU
Hungary
Prior art keywords
combination therapy
antitumor antibiotic
antitumor
antibiotic
therapy
Prior art date
Application number
HUE14175259A
Other languages
English (en)
Inventor
Ocaòa Victoria Moneo
Fernandez Luis Francisco Garcia
Carlos Maria Galmarini
Navarro Maria Jose Guillen
Marin Pablo Manuel Aviles
Nuòez Gema Santamaria
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of HUE042802T2 publication Critical patent/HUE042802T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE14175259A 2010-11-12 2011-11-11 Kombinációs terápia tumorellenes antibiotikummal HUE042802T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382300 2010-11-12

Publications (1)

Publication Number Publication Date
HUE042802T2 true HUE042802T2 (hu) 2019-07-29

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE14175282A HUE049389T2 (hu) 2010-11-12 2011-11-11 Kombinált terápia topoizomeráz inhibitorral
HUE14175268A HUE042801T2 (hu) 2010-11-12 2011-11-11 Kombinációs terápia mitózisgátlóval
HUE11781807A HUE027516T2 (hu) 2010-11-12 2011-11-11 Kombinációs terápia tumorellenes alkaloiddal
HUE14175259A HUE042802T2 (hu) 2010-11-12 2011-11-11 Kombinációs terápia tumorellenes antibiotikummal

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HUE14175282A HUE049389T2 (hu) 2010-11-12 2011-11-11 Kombinált terápia topoizomeráz inhibitorral
HUE14175268A HUE042801T2 (hu) 2010-11-12 2011-11-11 Kombinációs terápia mitózisgátlóval
HUE11781807A HUE027516T2 (hu) 2010-11-12 2011-11-11 Kombinációs terápia tumorellenes alkaloiddal

Country Status (24)

Country Link
US (5) US20130266666A1 (hu)
EP (6) EP2786755A3 (hu)
JP (4) JP6382516B2 (hu)
KR (9) KR20170096224A (hu)
CN (3) CN103282037B (hu)
AU (4) AU2011328004C1 (hu)
BR (4) BR122017028568B1 (hu)
CA (4) CA2995033C (hu)
CY (4) CY1117466T1 (hu)
DK (4) DK2786756T3 (hu)
ES (4) ES2719091T3 (hu)
HK (5) HK1202422A1 (hu)
HR (4) HRP20160361T1 (hu)
HU (4) HUE049389T2 (hu)
LT (3) LT2786753T (hu)
ME (3) ME03501B (hu)
PL (4) PL2786756T3 (hu)
PT (3) PT2786753T (hu)
RS (4) RS58608B1 (hu)
RU (4) RU2605335C2 (hu)
SI (4) SI2786756T1 (hu)
SM (1) SMT201600112B (hu)
TR (2) TR201903859T4 (hu)
WO (1) WO2012062920A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
PL2786756T3 (pl) * 2010-11-12 2020-07-13 Pharma Mar, S.A. Terapia skojarzona z inhibitorem topoizomerazy
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
EP3292218A4 (en) * 2015-01-30 2019-01-16 Glax LLC COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, FORECASTING, DETECTION AND TREATMENT OF CANCER
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
US20230027502A1 (en) * 2019-11-21 2023-01-26 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus
CN115835864A (zh) * 2020-07-01 2023-03-21 国立癌症中心 包含3-酮脂酰辅酶a硫解酶抑制剂以及肉碱酰基肉碱载体抑制剂的用于预防或治疗癌症的药物组合物
CN118576599A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN113633631B (zh) * 2021-06-17 2022-08-09 中国医学科学院医药生物技术研究所 米铂脂质体在抗耐药性肿瘤的应用
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof
WO2024188978A1 (en) * 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1999051238A1 (en) 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
NZ508585A (en) 1998-05-11 2002-11-26 Pharma Mar S Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
EP1280809B1 (en) 2000-04-12 2005-07-06 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
PL361389A1 (en) * 2000-11-06 2004-10-04 Pharma Mar, S.A. Effective antitumour treatments
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP3835763B2 (ja) 2002-08-19 2006-10-18 ファイザー・プロダクツ・インク 増殖亢進疾患のための組み合わせ治療
MXPA05004133A (es) * 2002-10-18 2005-10-05 Pharma Mar Sau Nuevos compuestos antitumorales.
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
WO2005115391A1 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Method for treating abnormal cell growth
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
PT1827437E (pt) * 2004-12-15 2012-01-12 Sigma Tau Ind Farmaceuti Combinação de agentes terapêuticos para o tratamento do cancro
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
HUE028055T2 (hu) * 2006-02-28 2016-11-28 Pharma Mar Sa Myeloma multiplex feljavított kezelése
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
PL2786756T3 (pl) * 2010-11-12 2020-07-13 Pharma Mar, S.A. Terapia skojarzona z inhibitorem topoizomerazy

Also Published As

Publication number Publication date
EP2786753B1 (en) 2019-01-09
CN106860870A (zh) 2017-06-20
KR20170057472A (ko) 2017-05-24
TR201903859T4 (tr) 2019-04-22
LT2786756T (lt) 2020-05-11
EP2786754A3 (en) 2014-10-29
RU2016144668A3 (hu) 2020-03-25
JP2018100303A (ja) 2018-06-28
PL2786753T3 (pl) 2019-09-30
SMT201600112B (it) 2016-07-01
CA2995033C (en) 2020-04-28
ES2569180T3 (es) 2016-05-09
RU2767664C2 (ru) 2022-03-18
EP3666275A3 (en) 2020-09-09
EP2786756A3 (en) 2014-10-29
US20180078550A1 (en) 2018-03-22
RU2605335C2 (ru) 2016-12-20
DK2786753T3 (en) 2019-04-15
HK1188572A1 (zh) 2014-05-09
AU2017276155A1 (en) 2018-01-04
SI2637663T1 (sl) 2016-05-31
BR122017028570B1 (pt) 2022-03-03
RU2018102078A (ru) 2019-07-19
EP2786753A2 (en) 2014-10-08
BR122017028566B1 (pt) 2022-03-03
BR112013011480A8 (pt) 2018-01-02
CA2817420A1 (en) 2012-05-18
EP2786753A3 (en) 2014-10-29
HRP20200696T1 (hr) 2020-07-24
CA2995018C (en) 2021-04-20
AU2016200191A1 (en) 2016-02-04
ES2719052T3 (es) 2019-07-08
JP2018100302A (ja) 2018-06-28
KR102247982B1 (ko) 2021-05-04
SI2786756T1 (sl) 2020-07-31
ES2719091T3 (es) 2019-07-08
EP2786756A2 (en) 2014-10-08
KR20130140071A (ko) 2013-12-23
RS54648B1 (en) 2016-08-31
PL2786756T3 (pl) 2020-07-13
CN103282037A (zh) 2013-09-04
KR20170096224A (ko) 2017-08-23
SI2786754T1 (sl) 2019-05-31
BR122017028568B1 (pt) 2022-03-03
WO2012062920A1 (en) 2012-05-18
RU2018102080A (ru) 2019-07-19
DK2637663T3 (en) 2016-04-18
KR20160088956A (ko) 2016-07-26
US20180008602A1 (en) 2018-01-11
ME03408B (me) 2020-01-20
ES2790414T3 (es) 2020-10-27
KR20170096065A (ko) 2017-08-23
RU2016144668A (ru) 2018-12-18
CN106860870B (zh) 2020-03-31
HK1202423A1 (en) 2015-10-02
KR20190130078A (ko) 2019-11-20
RS60236B1 (sr) 2020-06-30
ME03501B (me) 2020-04-20
EP2786754B1 (en) 2019-01-09
RS58609B1 (sr) 2019-05-31
KR102452022B1 (ko) 2022-10-06
US20180078551A1 (en) 2018-03-22
DK2786756T3 (en) 2020-04-27
EP2637663A1 (en) 2013-09-18
AU2011328004A1 (en) 2013-05-30
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
JP6724055B2 (ja) 2020-07-15
CA2995025C (en) 2020-04-28
AU2017276157A1 (en) 2018-01-04
US20230404999A1 (en) 2023-12-21
HRP20190565T1 (hr) 2019-05-17
JP2013542241A (ja) 2013-11-21
HUE027516T2 (hu) 2016-10-28
RU2013126630A (ru) 2014-12-20
RU2018102080A3 (hu) 2021-04-12
CN103282037B (zh) 2017-04-05
LT2786754T (lt) 2019-04-10
AU2011328004B2 (en) 2016-07-14
KR20210046853A (ko) 2021-04-28
HK1202421A1 (en) 2015-10-02
KR102301175B1 (ko) 2021-09-10
CY1117466T1 (el) 2017-04-26
CA2995018A1 (en) 2012-05-18
KR20170124641A (ko) 2017-11-10
CY1121501T1 (el) 2020-05-29
DK2786754T3 (en) 2019-04-15
EP2786755A3 (en) 2014-10-29
EP2786756B1 (en) 2020-03-11
ME02395B (me) 2016-09-20
AU2017276155B2 (en) 2019-03-07
EP2786754A2 (en) 2014-10-08
TR201904459T4 (tr) 2019-05-21
CY1122904T1 (el) 2021-10-29
CY1121504T1 (el) 2020-05-29
EP3666275A2 (en) 2020-06-17
JP6382516B2 (ja) 2018-08-29
RU2757373C2 (ru) 2021-10-14
AU2017276157B2 (en) 2019-03-07
HRP20190554T1 (hr) 2019-05-03
PT2786754T (pt) 2019-04-24
JP6723815B2 (ja) 2020-07-15
CA2995033A1 (en) 2012-05-18
HK1202419A1 (en) 2015-10-02
HK1202422A1 (en) 2015-10-02
RU2743643C2 (ru) 2021-02-20
RU2018102078A3 (hu) 2021-04-20
AU2016200191B2 (en) 2018-01-18
CA2817420C (en) 2019-09-24
HUE049389T2 (hu) 2020-09-28
CA2995025A1 (en) 2012-05-18
CN105664165A (zh) 2016-06-15
PT2786756T (pt) 2020-05-07
EP2786755A2 (en) 2014-10-08
RS58608B1 (sr) 2019-05-31
KR101716804B1 (ko) 2017-03-15
HUE042801T2 (hu) 2019-07-29
SI2786753T1 (sl) 2019-05-31
EP2637663B1 (en) 2016-02-24
JP2016138133A (ja) 2016-08-04
JP6724056B2 (ja) 2020-07-15
PT2786753T (pt) 2019-04-24
PL2637663T3 (pl) 2016-08-31
US11590129B2 (en) 2023-02-28
BR112013011480A2 (pt) 2016-08-09
US20130266666A1 (en) 2013-10-10
AU2011328004C1 (en) 2017-01-19
BR112013011480B1 (pt) 2022-03-22
PL2786754T3 (pl) 2019-07-31
HRP20160361T1 (hr) 2016-05-06

Similar Documents

Publication Publication Date Title
HRP20190554T1 (hr) Kombinacijska terapija s protutumorskim antibiotikom
HUS1800042I1 (hu) Antivirális terápia
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
ZA201401952B (en) Immunocytokine combination therapy
GB201016139D0 (en) Cancer phosholipidome
ZA201300967B (en) Combination anti-cancer therapy
GB201000346D0 (en) Headphones
EP2585115A4 (en) ANTICANCER TREATMENT
GB201005394D0 (en) Therapy
EP2629766A4 (en) COMBINATION THERAPY
GB201020513D0 (en) Cancer therapy
AU335296S (en) Headphones
AU2010905198A0 (en) Cancer therapy
AU2011904279A0 (en) Combination Therapy
AU2011902623A0 (en) Combination therapy
AU2011900060A0 (en) Combination Therapy